Updates
** Shares of CSL CSL.AX rise as much as 3.1% to A$249.17, hitting its highest level since May 30
** Stock marks largest intraday pct. gain since mid May
** Biotech giant says it plans to trim its research and development division across six global locations
** Co to also rely more on external partnerships, eyeing a reduction of its internal workforce
** CSL did not provide details on the job reductions in its emailed statement to Reuters
** We are streamlining the R&D organisation to foster collaboration, reduce duplication and improve efficiencies and we are simplifying our operating model - CSL spokesperson
** Co's statement comes a day after the Australian Financial Review reported CSL may cut around one-third of its 2,500 R&D staff
** Stock down 11.8% YTD, including the day's moves
(Reporting by Nichiket Sunil and Nikita Maria Jino in Bengaluru)
((Nichiket.Sunil@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。